Banff Foundation for Allograft Pathology and Paris Institute for Transplantation and Organ Regeneration (Banff-PITOR) 2024 C3G

Banff Foundation for Allograft Pathology and Paris Institute for Transplantation and Organ Regeneration (Banff-PITOR) 2024

Pegcetacoplan for post-transplant recurrent C3G or IC-MPGN in NOBLE: 12-week evolution
Access Resources

Pegcetacoplan maintains early improvements in post-transplant recurrent C3G and IC-MPGN: 1-year results from the phase 2 NOBLE trial
Access Resources

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available fo rthe uses being investigated.